No connection

Search Results

ADUS vs MESO

ADUS
Addus HomeCare Corporation
NEUTRAL
Price
$101.35
Market Cap
$1.88B
Sector
Healthcare
AI Confidence
78%
MESO
Mesoblast Limited
BEARISH
Price
$14.70
Market Cap
$1.92B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ADUS
19.42
MESO
--
Forward P/E
ADUS
13.61
MESO
-210.0
P/B Ratio
ADUS
1.69
MESO
32.96
P/S Ratio
ADUS
1.32
MESO
29.42
EV/EBITDA
ADUS
12.34
MESO
-294.48

Profitability

Gross Margin
ADUS
32.47%
MESO
-35.53%
Operating Margin
ADUS
11.25%
MESO
-55.16%
Profit Margin
ADUS
6.74%
MESO
-144.33%
ROE
ADUS
9.33%
MESO
-18.22%
ROA
ADUS
6.13%
MESO
-6.16%

Growth

Revenue Growth
ADUS
25.6%
MESO
1526.8%
Earnings Growth
ADUS
52.1%
MESO
--

Financial Health

Debt/Equity
ADUS
0.16
MESO
0.24
Current Ratio
ADUS
1.8
MESO
1.58
Quick Ratio
ADUS
1.63
MESO
1.35

Dividends

Dividend Yield
ADUS
--
MESO
--
Payout Ratio
ADUS
0.0%
MESO
0.0%

AI Verdict

ADUS NEUTRAL

ADUS exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating a weak to stable foundation, and no Altman Z-Score available, which limits distress risk assessment. The stock trades at $101.35, below its intrinsic value of $153.99 and Graham Number of $83.83, suggesting potential undervaluation on a defensive basis. However, strong revenue and earnings growth (25.6% and 52.1% YoY) are tempered by bearish insider activity and a lack of dividend. Analysts maintain a 'buy' recommendation with a target of $140.23, reflecting optimism in future performance.

Strengths
Strong earnings growth of 52.1% YoY and 52.5% Q/Q
High revenue growth of 25.6% YoY, outpacing sector average
Attractive intrinsic value of $153.99, implying upside potential
Risks
Piotroski F-Score of 4/9 indicates weak financial strength and limited operational efficiency
Bearish insider sentiment with 19 sell transactions and $2.99M in sales over 6 months
No dividend and zero payout ratio, limiting income appeal
MESO BEARISH

MESO presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete absence of deterministic value markers like the Graham Number. While revenue growth is explosive (1526.8%), the company suffers from a catastrophic negative gross margin of -35.53%, meaning it loses money on its core product delivery. The valuation is extreme, with a Price-to-Book ratio of 32.96 and a Price-to-Sales ratio of 29.42, indicating the stock is priced for perfection despite consistent quarterly losses over several years.

Strengths
Explosive year-over-year revenue growth of 1526.80%
Low Debt-to-Equity ratio (0.24) indicating minimal leverage
Healthy short-term liquidity with a Current Ratio of 1.58
Risks
Negative Gross Margin (-35.53%) indicates a fundamentally flawed cost structure
Extreme valuation multiples (P/B 32.96, P/S 29.42) far exceeding industry norms
Chronic lack of profitability with negative earnings across 25 consecutive quarters

Compare Another Pair

ADUS vs MESO: Head-to-Head Comparison

This page compares Addus HomeCare Corporation (ADUS) and Mesoblast Limited (MESO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile